BUB1 serves as a biomarker for poor prognosis in liver hepatocellular carcinoma.

IF 2.9 4区医学 Q3 IMMUNOLOGY

BMC Immunology Pub Date : 2025-03-11 DOI:10.1186/s12865-025-00698-4

Lili Zhang, Yuzheng Zhuge, Jingbin Ni

{"title":"BUB1 serves as a biomarker for poor prognosis in liver hepatocellular carcinoma.","authors":"Lili Zhang, Yuzheng Zhuge, Jingbin Ni","doi":"10.1186/s12865-025-00698-4","DOIUrl":null,"url":null,"abstract":"Background: Hepatocellular carcinoma (HCC) is the most frequent kind of liver cancer with high morbidity and mortality rates worldwide. Altered expression of BUB1 (budding uninhibited by benzimidazole 1) gene leads to chromosome instability and aneuploidy. This study investigated the expression of BUB1 and its prognostic value as well as its correlation with immune cell infiltration and immune checkpoints in HCC.Results: Using the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases, we found that BUB1 was up-regulated in HCC, thus prompting us to validate this observation by immunohistochemistry on 57 HCC paraffin embedded tissues from Wuxi No.2 People's Hospital. Kaplan-Meier survival analysis revealed that HCC patients with high BUB1 expression had shorter overall survival (OS) time as well as progression-free interval (PFI), and disease-specific survival (DSS) time compared to the patients with low BUB1 expression. Besides, STRING database showed that the top 10 co-expression genes were mainly involved in the regulation of cell division during the mitosis. Gene Ontology (GO) analysis and the Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis showed that BUB1 had a connection to cancer related pathways. Lastly, The Tumor Immune Estimation Resource (TIMER) analysis found that BUB1 was positively related to immune cell infiltration and some immune checkpoint gene in HCC.Clinical trial number: Not applicable.Conclusions: Our present study demonstrated that BUB1 is a potential prognostic biomarker, and BUB1 may play a role in the tumor immune microenvironment in HCC.","PeriodicalId":9040,"journal":{"name":"BMC Immunology","volume":"26 1","pages":"20"},"PeriodicalIF":2.9000,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11895216/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12865-025-00698-4","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Hepatocellular carcinoma (HCC) is the most frequent kind of liver cancer with high morbidity and mortality rates worldwide. Altered expression of BUB1 (budding uninhibited by benzimidazole 1) gene leads to chromosome instability and aneuploidy. This study investigated the expression of BUB1 and its prognostic value as well as its correlation with immune cell infiltration and immune checkpoints in HCC.

Results: Using the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases, we found that BUB1 was up-regulated in HCC, thus prompting us to validate this observation by immunohistochemistry on 57 HCC paraffin embedded tissues from Wuxi No.2 People's Hospital. Kaplan-Meier survival analysis revealed that HCC patients with high BUB1 expression had shorter overall survival (OS) time as well as progression-free interval (PFI), and disease-specific survival (DSS) time compared to the patients with low BUB1 expression. Besides, STRING database showed that the top 10 co-expression genes were mainly involved in the regulation of cell division during the mitosis. Gene Ontology (GO) analysis and the Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis showed that BUB1 had a connection to cancer related pathways. Lastly, The Tumor Immune Estimation Resource (TIMER) analysis found that BUB1 was positively related to immune cell infiltration and some immune checkpoint gene in HCC.

Clinical trial number: Not applicable.

Conclusions: Our present study demonstrated that BUB1 is a potential prognostic biomarker, and BUB1 may play a role in the tumor immune microenvironment in HCC.

查看原文本刊更多论文

BUB1可作为肝癌预后不良的生物标志物。

背景：肝细胞癌（HCC）是世界范围内发病率和死亡率最高的一类肝癌。BUB1（不受苯并咪唑1抑制的出芽）基因表达改变导致染色体不稳定和非整倍体。本研究探讨了肝癌中BUB1的表达及其预后价值，以及与免疫细胞浸润和免疫检查点的关系。结果：利用基因表达图谱（Gene Expression Omnibus， GEO）和肿瘤基因组图谱（Cancer Genome Atlas， TCGA）数据库，我们发现BUB1在HCC中表达上调，因此我们对无锡市第二人民医院57例HCC石蜡包埋组织进行免疫组化验证。Kaplan-Meier生存分析显示，与低BUB1表达的HCC患者相比，高BUB1表达的HCC患者总生存期（OS）、无进展间期（PFI）和疾病特异性生存期（DSS）时间更短。此外，STRING数据库显示，前10位共表达基因主要参与有丝分裂过程中细胞分裂的调控。基因本体（GO）分析和京都基因与基因组百科全书（KEGG）分析表明，BUB1与癌症相关途径有关。最后，肿瘤免疫估计资源（Tumor Immune Estimation Resource， TIMER）分析发现，在HCC中，BUB1与免疫细胞浸润和某些免疫检查点基因呈正相关。临床试验号：不适用。结论：我们目前的研究表明，BUB1是一种潜在的预后生物标志物，并且BUB1可能在HCC的肿瘤免疫微环境中发挥作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BMC Immunology 医学-免疫学

CiteScore

5.50

自引率

0.00%

发文量

审稿时长

1 months

期刊介绍： BMC Immunology is an open access journal publishing original peer-reviewed research articles in molecular, cellular, tissue-level, organismal, functional, and developmental aspects of the immune system as well as clinical studies and animal models of human diseases.